Please login to the form below

Not currently logged in
Email:
Password:

Martin Shkreli

This page shows the latest Martin Shkreli news and features for those working in and with pharma, biotech and healthcare.

Profit: the ugly, dirty truth?

Profit: the ugly, dirty truth?

That's the ugly, dirty truth.”. One of the most infamous quotes (of many) from a certain Martin Shkreli, the so-called ‘Pharma Bro’, currently serving seven years for fraud in

Latest news

  • Theranos and its CEO settle 'massive fraud' charges Theranos and its CEO settle 'massive fraud' charges

    A separate case will proceed again Balwani. Holmes will, however, avoid jail time, unlike former Turing CEO Martin Shkreli, who was arrested in 2015 by the FBI on securities fraud charges

  • Connecting the dots Connecting the dots

    In a world like this, how many Marathons, Valeants and Martin Shkreli’s do you think there would be?

  • Making a list and checking it twice… Making a list and checking it twice…

    Let's start with an obvious one: prices and price increases. The hangover effect of Martin Shkreli and Valeant Pharmaceuticals in 2015 continued to haunt the industry along with new dramas

  • EpiDemic EpiDemic

    And the next egregious drug-pricing headline is yet to come. But like Valeant and Martin Shkreli before it, the EpiPen narrative teaches us some important lessons.

  • Retrophin rockets away as rare disease trial hits targets Retrophin rockets away as rare disease trial hits targets

    Last year, Retrophin was indirectly caught up in the scandal surrounding its founder Martin Shkreli - who was eventually fired by the board and faced allegations of using company stock to pay ... Sparsentan was brought into Retrophin's pipeline by

More from news
Approximately 5 fully matching, plus 7 partially matching documents found.

Latest Intelligence

  • Trust me, I’m from pharma Trust me, I’m from pharma

    However, controversies around drug pricing – fuelled by the unhelpful interventions of Martin Shkreli as the pin-up boy for big, bad pharma – have undermined progress and reinforced the view that the

  • Pharma deals in September 2015 Pharma deals in September 2015

    treat toxoplasmosis, being given a 5, 000% price increase ($13.50 per pill to $750), to “ fund future research into the disease” and the subsequent backlash against its CEO Martin Shkreli ... in net cash to fund its near-term development needs and

  • Pharma deals during February 2014 Pharma deals during February 2014

    According to Martin Shkreli, founder and CEO: “ We also intend to move quickly to pursue FDA approval of Chenodal for CTX.".

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...
World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...

Infographics